tegoprubart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
tegoprubart

GtoPdb Ligand ID: 14508

Synonyms: AT-1501 | AT1501

Compound class: Antibody

Comment: Tegoprubart (AT-1501) is a monoclonal antibody that targets human CD40 ligand (CD40LG; CD154). Signalling via the CD40-CD40L costimulatory pathway is a recognized mechanism that can drive transplant (graft) rejection and inhibition/blockade of this pathway is considered as a potential therapeutic approach to achieve transplant tolerance and graft survival [3-5]. Tegoprubart is modified to prevent FcγRII receptor-mediated platelet activation and reduce the risk of drug-induced thromboembolic events.

References
1. Anwar IJ, Berman DM, DeLaura I, Gao Q, Willman MA, Miller A, Gill A, Gill C, Perrin S, Ricordi C et al.. (2023) The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Sci Transl Med, 15 (711): eadf6376. [PMID:37647390]
2. FDA. Orphan Drug Designations and Approvals: tegoprubart. Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1122425
3. Perrin S, Magill M. (2022) The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis. Front Immunol, 13: 861471. [PMID:35464470]
4. Pinelli DF, Ford ML. (2015) Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance. Immunotherapy, 7 (4): 399-410. [PMID:25917630]
5. Zhang T, Pierson 3rd RN, Azimzadeh AM. (2015) Update on CD40 and CD154 blockade in transplant models. Immunotherapy, 7 (8): 899-911. [PMID:26268734]

References

1. Anwar IJ, Berman DM, DeLaura I, Gao Q, Willman MA, Miller A, Gill A, Gill C, Perrin S, Ricordi C et al.. (2023)
The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates.
Sci Transl Med, 15 (711): eadf6376. [PMID:37647390]

2. FDA.
Orphan Drug Designations and Approvals: tegoprubart.
Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1122425

3. Perrin S, Magill M. (2022)
The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis.
Front Immunol, 13: 861471. [PMID:35464470]

4. Pinelli DF, Ford ML. (2015)
Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.
Immunotherapy, 7 (4): 399-410. [PMID:25917630]

5. Zhang T, Pierson 3rd RN, Azimzadeh AM. (2015)
Update on CD40 and CD154 blockade in transplant models.
Immunotherapy, 7 (8): 899-911. [PMID:26268734]